TGF-beta and cancer
PRINCIPAL INVESTIGATORS
- Angels Fabra Fres
- Javier Vaquero Rodríguez
CLINICAL RESEARCHERS
- Josep Ramon Ferreres Riera
POSTDOCTORAL RESEARCHERS
- Maria Esther González Sanchez
PREDOCTORAL RESEARCHERS
- Irene Peñuelas Haro
- Macarena Herranz Iturbide
- Rut Espinosa Sotelo
- Raquel Ramos Martin
- Josep Amengual Segura
- Ana Cantos Cortes
SCIENTIFIC SUPPORT
- Antonia Vinyals Rioseco
- Esther Bertran Rodriguez
Cancer
Oncobell
Scientific production
12
PAPERS
Impact factor: 98,616
4 PUBLICATIONS IN FIRST DECILE
11 PUBLICATIONS IN FIRST QUARTILE
12 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Lobe C, Vallette M, Arbelaiz A, Gonzalez Sanchez E, Izquierdo L, Pellat A, Guedj N, Louis C, Paradis V, Banales JM, Coulouarn C, Housset C, Vaquero J*, Fouassier L. ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and tumor-stroma paracrine signaling. Hepatology. 2021;74(6):3194-3212. doi:10.1002/hep.32069. IF:17,43.
- NADPH oxidase 4 (Nox4) deletion accelerates liver regeneration in mice.
Herranz-Itúrbide M, López-Luque J, Gonzalez-Sanchez E, Caballero-Díaz D, Crosas-Molist E, Martín-Mur B, Gut M, Esteve-Codina A, Jaquet V, Jiang JX, Török NJ, Fabregat I*. Redox Biol. 2021 Apr;40:101841. doi: 10.1016/j.redox.2020.101841. Epub 2020 Dec 23.PMID: 33493901 . IF: 11.779 - Gonzalez Sanchez E*, El Mourabit H, Jager M, Clavel M, Moog S, Vaquero J, Ledent T, Cadoret A, Gautheron J, Fouassier L, Wendum D, Chignard N, Housset C. Cholangiopathy aggravation is caused by VDR ablation and alleviated by VDR-independent vitamin D signaling in ABCB4 knockout mice. Biochim. Biophys. Acta-Mol. Basis Dis. 2021;1867(4):166067-166067. doi:10.1016/j.bbadis.2020.166067. IF:5,19.
- Soukupova J, Malfettone A, Bertran E, Hernandez Alvarez MI, Penuelas Haro I, Dituri F, Giannelli G, Zorzano A, Fabregat I*. Epithelial-Mesenchymal Transition (EMT) Induced by TGF-beta in Hepatocellular Carcinoma Cells Reprograms Lipid Metabolism. Int. J. Mol. Sci. 2021;22(11):doi:10.3390/ijms22115543. IF:5,92.
- Sabate Llobera A, Mestres Marti J, Reynes Llompart G, Llado L, Mils K, Serrano T, Cortes Romera M, Bertran E, Fabregat I, Ramos E. 2-[F-18]FDG PET/CT as a Predictor of Microvascular Invasion and High Histological Grade in Patients with Hepatocellular Carcinoma. Cancers. 2021;13(11):doi:10.3390/cancers13112554. IF:6,64.
Research highlights
PROJECTS
11 Competitive projects
1 Non-competitive project
PUBLISHED WORKS
2 theses
INNOVATION
1 license
NETWORKS
CIBEREHD
Euro-Cholangio-Net
Redoxbiomed
Selected projects
- 21PSJ005. Dissecting the role of the hepatocyte Epidermal Growth Factor Receptor (EGFR) pathway in the cellular interactome within the liver fibrotic niche. . FUNDACIÓN RAMÓN ARECES. 2021-2024. IP:FABREGAT ROMERO,MARIA ISABEL.
- 20MEC015. Diseccionando el papel terapéutico de la NADPH oxidasa NOX4 en colangiocarcinoma por medio de secuenciación masiva de RNA en célula única (NOX4CHOL). (PID2019-108651RJ-I00). MINISTERIO DE CIENCIA E INNOVACIÓN (MICINN). 2020-2023. IP:Vaquero Rodríguez,JAVIER.
- 20MEC023. DESARROLLO PRECLÍNICO DE UN NUEVO ACTIVO MODULADOR DE LA FIBROSIS Y LA SENESCENCIA PARA EL TRATAMIENTO DE LA ENFERMEDAD DE HÍGADO GRASO NO-ALCOHÓLICO (HEPATOSEN). (RTC2019-007125-1). CIC BIOGUNE; FUNDACIO IDIBELL; INSTITUT RECERCA BIOMÉDICA DE BARCELONA; MINISTERIO DE CIENCIA E INNOVACIÓN (MICINN); SENOLYTIC THERAPEUTICS SL. 2020-2022. IP:FABREGAT ROMERO,MARIA ISABEL.
- 19MEC012. Nuevas aproximaciones experimentales para analizar el papel de la NADPH oxidasa NOX4 en regeneración y cáncer hepáticos. Relación con la vía del TGF-beta. (RTI2018-094079-B-I00). MINISTERIO DE CIENCIA E INNOVACIÓN (MICINN). 2019-2022. IP:FABREGAT ROMERO,MARIA ISABEL.
- 19FIS026. Uveal Melanoma and liver metastasis: predictive use of molecular alterations and therapeutic opportunities. (PI18/01131). INSTITUTO DE SALUD CARLOS III. 2019-2022. IP:CAMINAL MITJANA, JOSE MARIA ; CO-IP: FABRA FRES, ÀNGELS.